^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Non Small Cell Lung Cancer

    Related cancers:
    24h
    Preliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung Cancer (clinicaltrials.gov)
    P=N/A, N=12, Enrolling by invitation, Peking University People's Hospital
    New trial
    1d
    REHABIM: Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, University Hospital, Brest | Not yet recruiting --> Recruiting | Trial completion date: Mar 2029 --> Nov 2028 | Trial primary completion date: Mar 2029 --> May 2028
    Enrollment open • Trial completion date • Trial primary completion date • HEOR
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    1d
    PulmoPrint: In-vivo Fluorescence Molecular Bronchoscopy of Dur-valumab-680LT in Patients With Unresectable Stage III NSCLC After Chemoradiation (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University Medical Center Groningen
    New P2 trial
    |
    Imfinzi (durvalumab)
    1d
    CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
    1d
    REZILIENT1: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=284, Active, not recruiting, Cullinan Therapeutics Inc. | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    zipalertinib (CLN-081)
    1d
    FAHIC-Lung: A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung). (clinicaltrials.gov)
    P=N/A, N=336, Completed, Fondazione Policlinico Universitario Campus Bio-Medico | Recruiting --> Completed | N=180 --> 336
    Trial completion • Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    1d
    ADX-MRD-LC: A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC (clinicaltrials.gov)
    P=N/A, N=305, Active, not recruiting, Shanghai Chest Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    1d
    A P-body-related risk score predicts prognosis and immune microenvironment in lung adenocarcinoma. (PubMed, Transl Cancer Res)
    As these genes have extra-P-body functions, the score serves as a transcriptomic proxy for P-body component enrichment, not a direct measure of P-body activity. Despite this limitation, it offers a clinically useful tool for risk stratification and mechanistic hypotheses.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • YBX1 (Y-Box Binding Protein 1) • YWHAG (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Gamma)
    |
    HRD
    1d
    The flavonoid astragalin induces apoptosis in lung adenocarcinoma and correlates with a prognostic cell cycle gene signature associated with PANoptosis. (PubMed, Transl Cancer Res)
    Our study identifies a four-gene cell cycle signature associated with poor LUAD prognosis and demonstrates that astragalin induces apoptosis in LUAD cells. These genes are involved in a PANoptosis-related network, suggesting a potential mechanistic link requiring further validation.
    Journal • Gene Signature • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • TOP2A (DNA topoisomerase 2-alpha) • PLK1 (Polo Like Kinase 1) • CASP3 (Caspase 3) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3)
    1d
    Phagocytic remodeling in CD74High tumor-associated macrophages during brain metastasis of lung adenocarcinoma. (PubMed, Transl Cancer Res)
    The observed loss of phagocytic capacity reflects dynamic functional state transitions toward an inflammatory and hypoxic phenotype rather than the passive enrichment of a single subpopulation. These insights provide a single-cell evolutionary framework for metastasis-associated immune reprogramming and underscore the potential of CD74 as a target for therapeutic intervention.
    Journal
    |
    CD74 (CD74 Molecule) • SPP1 (Secreted Phosphoprotein 1)
    1d
    Comprehensive genomics and functional analyses identify SMARCAL1 as a key oncogenic regulator in lung adenocarcinoma. (PubMed, Transl Cancer Res)
    SMARCAL1 plays a pivotal role in the development of LUAD and exhibits promise in predicting the prognosis and therapeutic efficacy of this malignancy. It is a promising candidate for utilization as a biomarker for LUAD.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)